WallStSmart

DoorDash, Inc. Class A Common Stock (DASH)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DoorDash, Inc. Class A Common Stock generates 20% more annual revenue ($14.72B vs $12.22B). VRTX leads profitability with a 35.5% profit margin vs 6.3%. DASH appears more attractively valued with a PEG of 1.76. VRTX earns a higher WallStSmart Score of 66/100 (B-).

DASH

Hold

47

out of 100

Grade: D+

Growth: 7.3Profit: 5.5Value: 4.0Quality: 7.0
Piotroski: 5/9Altman Z: 1.94

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 6.7Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

DASHUndervalued (+9.2%)

Margin of Safety

+9.2%

Fair Value

$193.25

Current Price

$163.93

$29.32 discount

UndervaluedFair: $193.25Overvalued
VRTXUndervalued (+57.2%)

Margin of Safety

+57.2%

Fair Value

$992.87

Current Price

$429.82

$563.05 discount

UndervaluedFair: $992.87Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

DASH2 strengths · Avg: 9.5/10
Revenue GrowthGrowth
33.1%10/10

Revenue surging 33.1% year-over-year

Market CapQuality
$74.66B9/10

Large-cap with strong market position

VRTX6 strengths · Avg: 9.7/10
Profit MarginProfitability
35.5%10/10

Keeps 36 of every $100 in revenue as profit

Operating MarginProfitability
38.1%10/10

Strong operational efficiency at 38.1%

EPS GrowthGrowth
61.4%10/10

Earnings expanding 61.4% YoY

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$107.87B9/10

Large-cap with strong market position

Return on EquityProfitability
24.2%9/10

Every $100 of equity generates 24 in profit

Areas to Watch

DASH4 concerns · Avg: 3.3/10
PEG RatioValuation
1.764/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.944/10

Grey zone — moderate risk

Profit MarginProfitability
6.3%3/10

6.3% margin — thin

P/E RatioValuation
81.2x2/10

Premium valuation, high expectations priced in

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.104/10

Expensive relative to growth rate

P/E RatioValuation
25.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : DASH

The strongest argument for DASH centers on Revenue Growth, Market Cap. Revenue growth of 33.1% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 35.5% and operating margin at 38.1%.

Bear Case : DASH

The primary concerns for DASH are PEG Ratio, Altman Z-Score, Profit Margin. A P/E of 81.2x leaves little room for execution misses.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

DASH profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.

DASH carries more volatility with a beta of 1.87 — expect wider price swings.

DASH is growing revenue faster at 33.1% — sustainability is the question.

VRTX generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 47/100), backed by strong 35.5% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

DoorDash, Inc. Class A Common Stock

CONSUMER CYCLICAL · INTERNET RETAIL · USA

DoorDash, Inc. operates a logistics platform that connects merchants, consumers, and merchants in the United States and internationally. The company is headquartered in San Francisco, California.

Visit Website →

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?